
Nelson B. Moseley Ii
Examiner (ID: 16050, Phone: (571)272-6221 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 843 |
| Issued Applications | 496 |
| Pending Applications | 104 |
| Abandoned Applications | 257 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18468863
[patent_doc_number] => 20230203146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => ANG2-BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/185493
[patent_app_country] => US
[patent_app_date] => 2023-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25948
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185493
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/185493 | ANG2-BINDING MOLECULES | Mar 16, 2023 | Pending |
Array
(
[id] => 20473212
[patent_doc_number] => 20260015431
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-15
[patent_title] => CAR-iNKT CELL TECHNOLOGY EFFECTIVE IN KILLING CHOLANGIOCARCINOMA
[patent_app_type] => utility
[patent_app_number] => 18/559529
[patent_app_country] => US
[patent_app_date] => 2023-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559529
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/559529 | CAR-iNKT CELL TECHNOLOGY EFFECTIVE IN KILLING CHOLANGIOCARCINOMA | Mar 15, 2023 | Pending |
Array
(
[id] => 19065731
[patent_doc_number] => 20240100157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => MESOTHELIN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/184392
[patent_app_country] => US
[patent_app_date] => 2023-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18184392
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/184392 | MESOTHELIN BINDING PROTEINS | Mar 14, 2023 | Abandoned |
Array
(
[id] => 18879097
[patent_doc_number] => 20240002466
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/182308
[patent_app_country] => US
[patent_app_date] => 2023-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 122656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182308
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/182308 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | Mar 9, 2023 | Pending |
Array
(
[id] => 18582948
[patent_doc_number] => 20230265206
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/182277
[patent_app_country] => US
[patent_app_date] => 2023-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/182277 | ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER | Mar 9, 2023 | Pending |
Array
(
[id] => 18879175
[patent_doc_number] => 20240002544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => CD28 BISPECIFIC ANTIBODIES FOR TARGETED T CELL ACTIVATION
[patent_app_type] => utility
[patent_app_number] => 18/180116
[patent_app_country] => US
[patent_app_date] => 2023-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18180116
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/180116 | CD28 BISPECIFIC ANTIBODIES FOR TARGETED T CELL ACTIVATION | Mar 6, 2023 | Pending |
Array
(
[id] => 18656222
[patent_doc_number] => 20230302106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 18/114836
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18114836
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/114836 | TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS | Feb 26, 2023 | Abandoned |
Array
(
[id] => 18550770
[patent_doc_number] => 20230248770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => HUMAN LEUKOCYTE ANTIGEN RESTRICTED GAMMA DELTA T CELL RECEPTORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/170776
[patent_app_country] => US
[patent_app_date] => 2023-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18170776
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/170776 | HUMAN LEUKOCYTE ANTIGEN RESTRICTED GAMMA DELTA T CELL RECEPTORS AND METHODS OF USE THEREOF | Feb 16, 2023 | Abandoned |
Array
(
[id] => 18536124
[patent_doc_number] => 20230241211
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
[patent_app_type] => utility
[patent_app_number] => 18/160386
[patent_app_country] => US
[patent_app_date] => 2023-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28707
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -65
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160386
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/160386 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Jan 26, 2023 | Pending |
Array
(
[id] => 18939655
[patent_doc_number] => 20240034794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
[patent_app_type] => utility
[patent_app_number] => 18/062871
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51295
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062871
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | Dec 6, 2022 | Pending |
Array
(
[id] => 18375994
[patent_doc_number] => 20230151076
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/057069
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48437
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057069
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057069 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 17, 2022 | Pending |
Array
(
[id] => 20116043
[patent_doc_number] => 12365732
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Anti-CD96 antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/057152
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 18
[patent_no_of_words] => 45666
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 318
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057152
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057152 | Anti-CD96 antibodies and methods of use thereof | Nov 17, 2022 | Issued |
Array
(
[id] => 18250864
[patent_doc_number] => 20230077903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/054737
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054737
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054737 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 10, 2022 | Pending |
Array
(
[id] => 18582901
[patent_doc_number] => 20230265158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/054566
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054566
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054566 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 10, 2022 | Abandoned |
Array
(
[id] => 18468845
[patent_doc_number] => 20230203127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/054695
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48332
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054695
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054695 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 10, 2022 | Pending |
Array
(
[id] => 18391438
[patent_doc_number] => 20230159656
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/054426
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -68
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054426
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054426 | ANTI-STEAP1 ANTIGEN-BINDING PROTEIN | Nov 9, 2022 | Pending |
Array
(
[id] => 18643296
[patent_doc_number] => 11767356
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-09-26
[patent_title] => Canine parvovirus nanobody CPV-VHH-E3 and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/983727
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 10306
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983727
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983727 | Canine parvovirus nanobody CPV-VHH-E3 and application thereof | Nov 8, 2022 | Issued |
Array
(
[id] => 18529947
[patent_doc_number] => 20230235014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/052738
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052738
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052738 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 3, 2022 | Abandoned |
Array
(
[id] => 18529948
[patent_doc_number] => 20230235015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/052796
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052796
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052796 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 3, 2022 | Abandoned |
Array
(
[id] => 18529949
[patent_doc_number] => 20230235016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
[patent_app_type] => utility
[patent_app_number] => 18/052824
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052824
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052824 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Nov 3, 2022 | Pending |